TY - JOUR
T1 - Hormonal replacement therapy after gynaecological cancer
AU - Biglia, Nicoletta
AU - Mariani, Luca
AU - Marenco, Davide
AU - Robba, Claudio
AU - Peano, Elisa
AU - Kubatzki, Franziska
AU - Sismondi, Piero
PY - 2006/10
Y1 - 2006/10
N2 - Thousands of women are treated each year for gynaecological cancers; many of these are already in menopause, while other younger patients will go into early menopause due to surgery, chemotherapy and/or radiotherapy to the pelvic region. The aim of this paper is to review the biological and clinical evidence in favour and against hormone replacement therapy (HRT) use after gynaecological cancers. With the exception of breast and endometrial cancer, there is no biological evidence that HRT may increase the recurrence risk. In women with previous endometrial cancer, HRT use is not supported by univocal and conclusive data to formulate specific recommendations, whereas most authors suggest that oestrogens may be used after adequate information about risks and benefits. The use of HRT in breast cancer patients is, at present, considered contra-indicated, even if results of clinical trials are not concordant. Therapeutic nonhormonal alternatives may be proposed to these patients.
AB - Thousands of women are treated each year for gynaecological cancers; many of these are already in menopause, while other younger patients will go into early menopause due to surgery, chemotherapy and/or radiotherapy to the pelvic region. The aim of this paper is to review the biological and clinical evidence in favour and against hormone replacement therapy (HRT) use after gynaecological cancers. With the exception of breast and endometrial cancer, there is no biological evidence that HRT may increase the recurrence risk. In women with previous endometrial cancer, HRT use is not supported by univocal and conclusive data to formulate specific recommendations, whereas most authors suggest that oestrogens may be used after adequate information about risks and benefits. The use of HRT in breast cancer patients is, at present, considered contra-indicated, even if results of clinical trials are not concordant. Therapeutic nonhormonal alternatives may be proposed to these patients.
KW - Gynaecological and breast cancer survivors
KW - Hormone replacement therapy
KW - Menopause
UR - http://www.scopus.com/inward/record.url?scp=33750462730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750462730&partnerID=8YFLogxK
U2 - 10.1159/000095727
DO - 10.1159/000095727
M3 - Article
C2 - 17068403
AN - SCOPUS:33750462730
VL - 46
SP - 191
EP - 196
JO - Gynakologisch-geburtshilfliche Rundschau
JF - Gynakologisch-geburtshilfliche Rundschau
SN - 1018-8843
IS - 4
ER -